Abstract
Paliperidone is an antipsychotic recently made available in the US and UK in a special oral extended release form. Paliperidone is a modified form of risperidone namely 9-hydroxyrisperidone, (itself the active metabolite of risperidone). Since risperidone has been available for many years some argue that paliperidone is not a novel antipsychotic but a newly marketed variant. An injectable form, paliperidone palmitate is being trialled. Paliperidone is mainly excreted renally and there is only limited hepatic metabolism. Paliperidone works by partially blocking D2 dopamine receptors and fully blocking serotonin. The normal dosing range for paliperidone is 3-12 mg daily. Efficacy studies with paliperidone indicate that it is effective against schizophrenia and also has a similar side effect profile compared to other antipsychotics. There is an absence of effects on glucose and lipids in comparison with olanzapine. Symptom reduction in schizophrenia occurs as soon as day four of treatment with paliperidone. Clinical experience with risperidone over many years suggests that paliperidone would have a valuable role as an antipsychotic. The entity is not truly novel, but rather than being a variant existing purely for marketing purposes, should be regarded as an upgrade.
Keywords: Paliperidone, antipsychotic, active metabolite, Clinical Review, hepatic metabolism, serotonin, schizophrenia
Current Drug Therapy
Title: Paliperidone: A Clinical Review
Volume: 4 Issue: 1
Author(s): Ben Green
Affiliation:
Keywords: Paliperidone, antipsychotic, active metabolite, Clinical Review, hepatic metabolism, serotonin, schizophrenia
Abstract: Paliperidone is an antipsychotic recently made available in the US and UK in a special oral extended release form. Paliperidone is a modified form of risperidone namely 9-hydroxyrisperidone, (itself the active metabolite of risperidone). Since risperidone has been available for many years some argue that paliperidone is not a novel antipsychotic but a newly marketed variant. An injectable form, paliperidone palmitate is being trialled. Paliperidone is mainly excreted renally and there is only limited hepatic metabolism. Paliperidone works by partially blocking D2 dopamine receptors and fully blocking serotonin. The normal dosing range for paliperidone is 3-12 mg daily. Efficacy studies with paliperidone indicate that it is effective against schizophrenia and also has a similar side effect profile compared to other antipsychotics. There is an absence of effects on glucose and lipids in comparison with olanzapine. Symptom reduction in schizophrenia occurs as soon as day four of treatment with paliperidone. Clinical experience with risperidone over many years suggests that paliperidone would have a valuable role as an antipsychotic. The entity is not truly novel, but rather than being a variant existing purely for marketing purposes, should be regarded as an upgrade.
Export Options
About this article
Cite this article as:
Green Ben, Paliperidone: A Clinical Review, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081903
DOI https://dx.doi.org/10.2174/157488509787081903 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progesterone Receptor Membrane Component 1 and its Accomplice:
Emerging Therapeutic Targets in Lung Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokines and Their Receptors in Chronic Pulmonary Disease
Current Drug Targets - Inflammation & Allergy Progress in Detection of Insomnia Sleep Disorder: A Comprehensive Review
Current Drug Targets Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Neuroimaging and Genetics of Antidepressant Response to Sleep Deprivation: Implications for Drug Development
Current Pharmaceutical Design Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From Orphan Targets to Innovative New Antibiotic Drugs
Current Medicinal Chemistry Ability to Adjust in Length and Damping: Missing Features in Middle Ear Implants?
Recent Patents on Biomedical Engineering (Discontinued) Use of Dopaminergic Agents in the Treatment-Resistant Depression
Current Psychopharmacology Microemulsions Based Transdermal Drug Delivery Systems
Current Drug Discovery Technologies Sodium-Assisted Formation of Binding and Traverse Conformations of the Substrate in a Neurotransmitter Sodium Symporter Model
Current Drug Discovery Technologies Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents
Medicinal Chemistry Sleep Disturbances and Cognitive Impairment in the Course of Type 2 Diabetes-A Possible Link
Current Neuropharmacology Microcirculation in Sepsis: New Perspectives
Current Vascular Pharmacology